Brief: Windtree Completes Enrollment Of Phase 2 Study Of Istaroxime In Early Cardiogenic Shock
15/03/2022 11:17
March 15 (Reuters) - Windtree Therapeutics Inc WINT.O :
* WINDTREE COMPLETES ENROLLMENT OF PHASE 2 STUDY OF
ISTAROXIME IN
EARLY CARDIOGENIC SHOCK
Source text for Eikon: ID:nGNX3zr1Nz
Further company coverage: WINT.O
Recent news on Windtree Therapeutics
See all newsBrief: Windtree Therapeutics Announces It Has Signed A Letter Of Intent To Acquire Commloan
Brief: Windtree Therapeutics Announces It May Receive License Agreement Payments From Its Licensee For Renewed Acute Pulmonary Development By The Licensee
Brief: Windtree Therapeutics Stockholders Approve Key Proposals For Revenue And Profit Generation At The Special Stockholder Meeting
Brief: Windtree Therapeutics Terminates Seismic-C Clinical Study At 20 Enrollments - SEC Filing
Brief: Windtree Therapeutics Inc - Announces Interim Analysis Of Istaroxime Phase 2 Study